Semaglutide Providers in Texas
GLP1Search tracks 34 Semaglutide provider records across 8 Texas cities. Use this page to compare provider density, upstream source flags, public pricing coverage, and local markets before contacting a clinic.
Provider Records
34
Cities
8
Source Flagged
1
Public Pricing
12
Medication Market Snapshot
Semaglutide access signals in Texas
Semaglutide: a GLP-1 receptor agonist used in diabetes and chronic weight-management care In the GLP1Search directory, the strongest Texas city clusters for Semaglutide are Houston (8), Austin (6), Dallas (6), Fort Worth (5). Directory records show 97% data completeness, 35% public-pricing coverage, and 3% upstream source/place flag coverage for this state-medication segment. Source flags are not verified-provider counts and do not by themselves confirm current treatment availability.
Data Complete
97%
Pricing Visible
35%
Source Flagged
3%
Top Texas cities for Semaglutide
Featured Semaglutide provider records in Texas
Patient Updates
Get new Semaglutide listings for Texas
Join the GLP1Search update list for provider additions, pricing changes, and source-flag notes in this market.
No spam. Unsubscribe anytime.
Clinic Claim
Claim or update a Texas listing
Clinics can submit Semaglutide availability, pricing, source details, clinical oversight, and contact information for review.
Claim Provider ListingProvider submissions go through GLP1Search review before publishing.
All Texas cities with Semaglutide listings
Questions about Semaglutide providers in Texas
How many providers are listed?
GLP1Search lists 34 Semaglutide provider records across 8 cities in Texas.
Which cities have the most listings?
Houston (8), Austin (6), Dallas (6), Fort Worth (5), San Antonio (5) currently have the highest Semaglutide listing density in Texas.
Are brand examples the same as availability?
No. Ozempic, Wegovy, and Rybelsus are brand examples associated with Semaglutide. Actual availability depends on the clinic, prescription eligibility, insurance, pharmacy sourcing, and current regulatory status.